Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence

NCT05062096 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT05062096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05062096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Not applicable
Overall status
Unknown status
Start date
November 1, 2022
Completion date
December 2, 2023
Enrollment
220 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma